Ceruletide Diethylamine
FDA-approved product (injectable, injection), marketed as Tymtran.
- Registered studies
- 0
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLNo approved indication recorded
ChEMBL records no approved indication for Ceruletide Diethylamine. Its therapeutic class is shown instead.
- WHO therapeutic group
- Tests for bile duct patency
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA62.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli46.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae39.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis54.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
No evidence found
The registry was searched and no registered study names this medicine.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Ceruletide Diethylamine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Amphotericin BExisting use: Aspergillosis, Candidiasis, Cryptococcal meningitis and 7 more54.7% AI-predicted activityagainst MRSA50+ registered studies
- Prazosin HydrochlorideExisting use: Diabetes mellitus, Hypertension54.7% AI-predicted activityagainst MRSA50+ registered studies
- AlprazolamExisting use: Anxiety, Anxiety disorder, Generalized anxiety disorder and 1 more54.6% AI-predicted activityagainst MRSA50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more54.6% AI-predicted activityagainst MRSA50+ registered studies
- Fondaparinux SodiumExisting use: Deep vein thrombosis, Intermediate coronary syndrome, Myocardial infarction and 3 more54.6% AI-predicted activityagainst MRSA50+ registered studies
- RevefenacinExisting use: Airway obstruction, Chronic obstructive pulmonary disease54.6% AI-predicted activityagainst MRSA20 registered studies
- CobicistatExisting use: HIV infection, HIV-1 infection, Infection54.6% AI-predicted activityagainst MRSA50+ registered studies
- ErdafitinibExisting use: Bladder tumor, Cancer, Neoplasm and 2 more54.6% AI-predicted activityagainst MRSA43 registered studies
- AvanafilExisting use: Erectile dysfunction, Impotence54.5% AI-predicted activityagainst MRSA24 registered studies
- Conivaptan HydrochlorideExisting use: Cardiovascular disease, Heart failure54.5% AI-predicted activityagainst MRSA21 registered studies
- DasatinibExisting use: Acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 7 more54.4% AI-predicted activityagainst MRSA50+ registered studies
- OdevixibatExisting use: Intrahepatic cholestasis54.4% AI-predicted activityagainst MRSA13 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
No evidence found: the registry was searched and no registered study names this medicine.